Skip to main content
. 2017 Oct;58(10):1553–1559. doi: 10.2967/jnumed.117.189944

FIGURE 5.

FIGURE 5.

The IEDDA ligation (A); the 2 components of IEDDA-based pretargeting system: a TCO-bearing immunoconjugate and a tetrazine-modified radioligand (B); SPECT/CT image of an LS174T tumor-bearing mouse pretargeted with CC49-TCO and 111In-DOTA-tetrazine (reprinted with permission of reference (34)) (C); and a longitudinal study of normalized tumor volume in mice bearing BxPC3 pancreatic ductal adenocarcinoma xenografts treated with a PRIT regimen composed of 5B1-TCO and 177Lu-DOTA-PEG7-tetrazine (reprinted with permission of (41)) (D).